A new antibiotic that has the potential to save millions of lives has entered its last phase of human testing. Swiss ...

An experimental antibiotic, zosurabalpin, to fight a deadly superbug has entered the final human trials. Currently, no new antibiotics targeting this superbug have been developed in over five decades.

A new antibiotic that could treat a common ‘superbug’ is to be tested on patients. The drug Zosurabalpin, is being developed ...

A new study is the first phase 3 to show meaningful improvement in both progression-free and overall survival with first-line ...

If successful, it would be the first new class of drug against certain bacteria strains for more than fifty years ...

The Swiss pharma has inked several collaborations in this field, suggesting it sees the approach as promising to rid the body ...

As the administration pushes for a return to US manufacturing, outsourcing agreements with domestic manufacturers are ...

The Itovebi-based regimen is approved for the treatment of adults with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer in the United ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year follow-up data from the Phase III STARGLO study. After a median follow-up of 24.7 months, data showed a 40 ...

The strategic collaboration with Broad Clinical Labs will explore and develop applications using Roche's SBX sequencing technology1, with an initial focus on critically ill newborns and their parents.

"Integrating the SBX technology into clinical and translational pipelines opens exciting new possibilities,” said Niall ...

Updated data from the pivotal phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall surviva ...